# Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.

> **NCT04247165** · PHASE1,PHASE2 · COMPLETED · sponsor: **Herlev Hospital** · enrollment: 55 (actual)

## Conditions studied

- Borderline Resectable, Locally Advanced or Metastatic Pancreatic Cancer

## Interventions

- **DRUG:** Gemcitabine
- **DRUG:** Nab-paclitaxel
- **DRUG:** Nivolumab
- **DRUG:** Ipilimumab
- **RADIATION:** SBRT

## Key facts

- **NCT ID:** NCT04247165
- **Lead sponsor:** Herlev Hospital
- **Sponsor class:** OTHER
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2020-06-02
- **Primary completion:** 2024-05-24
- **Final completion:** 2024-12-05
- **Target enrollment:** 55 (ACTUAL)
- **Last updated:** 2025-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04247165

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04247165, "Nivolumab, Ipilimumab and Chemoradiation in Pancreatic Cancer.". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT04247165. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*